Therapeutics News and Research

RSS
RXi Pharmaceuticals to present in vivo data of rxRNA compounds

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

EVEREST clinical trial results to be presented at the upcoming TCT Conference

EVEREST clinical trial results to be presented at the upcoming TCT Conference

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

GENova allies with academic institutions specializing in stem cell research

GENova allies with academic institutions specializing in stem cell research

Phase III EXTEND trial results of pixantrone announced

Phase III EXTEND trial results of pixantrone announced

BCLI collaborates with HBI to complete pre-clinical safety experiments

BCLI collaborates with HBI to complete pre-clinical safety experiments

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Halozyme Therapeutics to present its product development pipeline

Halozyme Therapeutics to present its product development pipeline

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Clinical trial data of Genous Bio-engineered R stent to be presented

Clinical trial data of Genous Bio-engineered R stent to be presented

Stem cell therapy holds great promise for regenerative medicine

Stem cell therapy holds great promise for regenerative medicine

Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress

Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Phase I results of Tobira's TBR-652 CCR5 antagonist for the treatment of HIV

Phase I results of Tobira's TBR-652 CCR5 antagonist for the treatment of HIV

Cardium to raise funds through private placement of common stock

Cardium to raise funds through private placement of common stock

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.